Skip to content

Evaluation of DeltaMaxx® Microcoil System in Intracranial Aneurysms

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01945827
Enrollment
0
Registered
2013-09-19
Start date
2014-01-31
Completion date
Unknown
Last updated
2014-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysms

Brief summary

The primary objective of this registry is to assess the safety and angiographic outcomes of endovascular treatment of intracranial aneurysms using the DeltaMaxx Microcoil System.

Interventions

DEVICEDeltaMaxx Microcoil System

Sponsors

Codman & Shurtleff
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Subject age ≥18 and ≤80 with a diagnosis of ruptured or unruptured intracranial aneurysm judged suitable for selective endovascular treatment by coil occlusion during single procedure * Investigator intends to use DeltaMaxx Microcoil system during coiling procedure * Investigator intends to use only Codman Neuro microcoils during coiling procedure * Aneurysm size \[largest measurement from the cross sectional images to determine overall aneurysm size, not just the lumen\] ≥6 mm * If ruptured aneurysm: Hunt and Hess 1, 2, or 3 * If unruptured aneurysm: Subject grade Modified Rankin Scale 0 - 2 * The subject or his/her Legally Authorized Representative must voluntarily provide Informed Consent for participation in this study and agree to return for all study visits.

Exclusion criteria

* Prior treatment (surgical or endovascular) of the target aneurysm * Subjects with more than one aneurysm (\>2 mm) that have been treated with endovascular or clipping techniques in the past 30 days. * Subject with social, medical or psychological conditions that interfere with treatment and follow-up evaluation * Women who are pregnant or plan to become pregnant during the study * Life expectancy less than 12 months. * Presence of arteriovenous malformation * Fusiform, mycotic, traumatic, or tumoral aneurysms * Planned aneurysm treatment by parent vessel occlusion * Subject enrolled in any concurrent study

Design outcomes

Primary

MeasureTime frameDescription
Primary Effectiveness Objective - Angiographic Outcomes12 MonthsThe Primary Effectiveness endpoint is the immediate post-procedure and 12-month angiographic occlusion rates assessed by the independent core lab using the modified Raymond-Roy Grading Scale (RRGS) scale
Primary Safety Endpoint - Neurological Morbidity and Mortality12 monthsNeurological Morbidity and Mortality as determined by the NIH Stroke Scale and all-cause mortality, regardless of relationship to the treatment, will be captured over the course of the study

Secondary

MeasureTime frameDescription
Packing Density24 hoursPacking density as measured by volumetric filling of the aneurysm post-procedure after the coils have been placed as indicated by angiographic films taken at the end of the coiling procedure
Recurrence Rate12 months
Re-treatment Rate12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026